OBJECTIVE-Glucagon-like peptide-1 (GLP-1) increases intracellular Ca 2ϩ concentrations ([Ca 2ϩ ] i ), resulting in insulin secretion from pancreatic -cells. The molecular mechanism(s) of the GLP-1-mediated regulation of [Ca 2ϩ ] i was investigated. 2ϩ ] i were measured in -cells isolated from Cd38 ϩ/ϩ and Cd38 Ϫ/Ϫ mice. Calcium-mobilizing second messengers were identified by measuring levels of nicotinic acid adenine dinucleotide phosphate (NAADP) and cyclic ADP-ribose (ADPR), using a cyclic enzymatic assay. To locate NAADP-and cyclic ADPRproducing enzyme(s), cellular organelles were separated using the sucrose gradient method. [Ca 2ϩ ] i increase showed a cooperative Ca 2ϩ signal, i.e., an initial [Ca 2ϩ ] i rise mediated by the action of NAADP that was produced in acidic organelles and a subsequent long-lasting increase of [Ca 2ϩ ] i by the action of cyclic ADPR that was produced in plasma membranes and secretory granules. GLP-1 sequentially stimulated production of NAADP and cyclic ADPR in the organelles through protein kinase A and cAMP-regulated guanine nucleotide exchange factor II. Furthermore, the results showed that NAADP production from acidic organelles governed overall Ca 2ϩ signals, including insulin secretion by GLP-1, and that in addition to CD38, enzymes capable of synthesizing NAADP and/or cyclic ADPR were present in -cells. These observations were supported by the study with Cd38 Ϫ/Ϫ -cells, demonstrating production of NAADP, cyclic ADPR, and Ca 2ϩ signal with normal insulin secretion stimulated by GLP-1.
RESEARCH DESIGN AND METHODS-GLP-1-induced changes in [Ca
RESULTS-A GLP-1-induced
CONCLUSIONS-Our
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.